Temperature-Controlled Catheter Ablation for Paroxysmal Atrial Fibrillation: The QDOT-MICRO Workflow Study
Author:
- Dhanunjaya LakkireddyDLDhanunjaya Lakkireddy
Open Access
- 31 October 2020
- journal article
- cardiology
- Published by Cardiofront, LLC in Journal of Atrial Fibrillation
- Vol. 13 (6) , 20200460
Abstract
Background A novel QDOT MICRO (Biosense Webster, Inc., Irvine, CA) catheter with optimized temperature control and microelectrodes was designed to incorporate real-time temperature sensing with contact force detection and microelectrodes to streamline ablation workflow. The QDOT-MICRO feasibility study evaluated the workflow, performance, and safety of temperature-controlled catheter ablation in patients with symptomatic paroxysmal atrial fibrillation with conventional ablation setting. Methods This was a non-randomized, single-arm, first-in-human study. The primary outcome was pulmonary vein isolation (PVI), confirmed by entrance block after adenosine and/or isoproterenol challenge. Safety outcomes included incidences of early-onset primary adverse events (AEs) and serious adverse device effects (SADEs). Device performance was evaluated via physician survey. Results All evaluated patients (n = 42) displayed 100% PVI. Two primary AEs (4.8%) were reported: 1 pericarditis and 1 vascular pseudoaneurysm. An additional SADE of localized infection was reported in 1 patient. No stroke, patient deaths, or other unanticipated AEs were reported. Average power delivered was 32.1±4.1 W, with a mean temperature of 40.8°C±1.6°C. Mean procedure (including 20-minute wait), fluoroscopy, and radiofrequency application times were 129.8, 6.7, and 34.0 minutes, respectively. On device performance, physicians reported overall satisfactory performance with the new catheter, with highest scores for satisfaction and usefulness of the temperature indicator. Conclusions Initial clinical experience with the novel catheter showed 100% acute PVI success and acceptable safety and device performance in temperature-controlled ablation mode. There were no deaths, stroke, or unanticipated AEs. Fluoroscopy and procedural times were short and similar or better than reported for prior generation catheters.Keywords
This publication has 13 references indexed in Scilit:
- 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summaryJournal of Arrhythmia, 2017
- Safety and efficiency of porous-tip contact-force catheter for drug-refractory symptomatic paroxysmal atrial fibrillation ablation: results from the SMART SF trialEP Europace, 2017
- Temperature-Controlled Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Atrial FibrillationJACC, 2017
- Relationship Between Catheter Stability and 12-Month Success After Pulmonary Vein IsolationJACC: Clinical Electrophysiology, 2016
- Long-term efficacy of catheter ablation as first-line therapy for paroxysmal atrial fibrillation: 5-year outcome in a randomised clinical trialHeart, 2016
- The Incidence of Audible Steam Pops Is Increased and Unpredictable With the ThermoCool® Surround Flow Catheter During Left Atrial Catheter Ablation: A Prospective Observational StudyJournal of Cardiovascular Electrophysiology, 2015
- Paroxysmal AF Catheter Ablation With a Contact Force Sensing CatheterJACC, 2014
- Acute Safety of an Open‐Irrigated Ablation Catheter with 56‐Hole Porous Tip for Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: Analysis from 2 Observational Registry StudiesJournal of Cardiovascular Electrophysiology, 2014
- Effects of Open‐Irrigated Radiofrequency Ablation Catheter Design on Lesion Formation and Complications: In Vitro Comparison of 6 Different DevicesJournal of Cardiovascular Electrophysiology, 2013
- Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial FibrillationJAMA, 2010